Correlation Between Lyell Immunopharma and Foghorn Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lyell Immunopharma and Foghorn Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lyell Immunopharma and Foghorn Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lyell Immunopharma and Foghorn Therapeutics, you can compare the effects of market volatilities on Lyell Immunopharma and Foghorn Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lyell Immunopharma with a short position of Foghorn Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lyell Immunopharma and Foghorn Therapeutics.

Diversification Opportunities for Lyell Immunopharma and Foghorn Therapeutics

0.54
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Lyell and Foghorn is 0.54. Overlapping area represents the amount of risk that can be diversified away by holding Lyell Immunopharma and Foghorn Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Foghorn Therapeutics and Lyell Immunopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lyell Immunopharma are associated (or correlated) with Foghorn Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Foghorn Therapeutics has no effect on the direction of Lyell Immunopharma i.e., Lyell Immunopharma and Foghorn Therapeutics go up and down completely randomly.

Pair Corralation between Lyell Immunopharma and Foghorn Therapeutics

Given the investment horizon of 90 days Lyell Immunopharma is expected to under-perform the Foghorn Therapeutics. In addition to that, Lyell Immunopharma is 1.32 times more volatile than Foghorn Therapeutics. It trades about -0.05 of its total potential returns per unit of risk. Foghorn Therapeutics is currently generating about 0.03 per unit of volatility. If you would invest  785.00  in Foghorn Therapeutics on September 2, 2024 and sell it today you would earn a total of  14.00  from holding Foghorn Therapeutics or generate 1.78% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Lyell Immunopharma  vs.  Foghorn Therapeutics

 Performance 
       Timeline  
Lyell Immunopharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lyell Immunopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
Foghorn Therapeutics 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Foghorn Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Foghorn Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Lyell Immunopharma and Foghorn Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lyell Immunopharma and Foghorn Therapeutics

The main advantage of trading using opposite Lyell Immunopharma and Foghorn Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lyell Immunopharma position performs unexpectedly, Foghorn Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Foghorn Therapeutics will offset losses from the drop in Foghorn Therapeutics' long position.
The idea behind Lyell Immunopharma and Foghorn Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Complementary Tools

Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets